All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On March 10–12 2017, the EHA-SWG meeting on Rare Lymphomas took place in Barcelona, Spain, and was jointly chaired by Prof. Martin Dreyling, from Klinikum der Universität München, Germany, and Prof. Maire José Kersten, from the Academic Medical Center, Amsterdam, The Netherlands.
On March 10th 2017, D. de Jong (VU University Medical Center, Amsterdam, The Netherlands) gave a talk during the CNS Lymphoma scientific session, which focused on the biology of CNS Lymphomas.
The talk began by explaining that immunodeficiency-related Lymphoproliferative Disorders (LPDs) make up a heterogeneous group; ranging from self-limiting hyperplasias to aggressive lymphomas. The WHO classification of immunodeficiency-related LPDs (2008 and 2016) is structured around 4 major categories, based on the immunodeficiency setting/background in which they arise: Post-Transplant Lymphoproliferative Disorders (PTLDs), lymphomas associated with Human Immunodeficiency Virus (HIV) infection, LPDs associated with primary immune disorders, and other iatrogenic immunodeficiency-associated LPDs.
It has been previously reported that immunosuppression for solid organ transplantation increases risk of LPD. Crane et al. (Oncotarget 2015) identified all PTLDs diagnosed over a 28-year time frame at their institution (total = 174 total, PCNS = 29) and all similar cases captured in the United Network for Organ Sharing-Organ Procurement and Transplant Network (UNOS-OPTN) data file.
D. De Jong then went on to state that PCNSL bears similarities to ABC-DLBCL, such as:
However, PCNSL does differ from ABC-DLBCL by its overall genetic profile:
It was also explained that constitutive TLR and BCR signaling are major mechanisms of PCNSL: NFKBIZ gain on chromosome 3 occurs in 40–60% of cases and functional studies highlight NFKBIZ as a functional signaling mechanism. D. de Jong also went on to say that translocations in MYC and BCL2 are extremely rare in PCNSL. Translocations do occur with BCL6 in 17–47% of cases, pairing with Ig- and non-Ig partners. It was also stated that constitutive activation of PD-1 and PD-ligand signaling is a key mechanism of immune evasion in PCNSL.
Moreover, D. de Jong stated that loss of β2M and HLA-I are not specific to PCNSL. HLA expression is lost in >50% of PCNSL cases. Moreover, PCNSL-tumor-Ig have a restricted IgV-spectrum and recognize self-antigens expressed in glial cells. VH-mutation pattern reveals extensive signs of somatic hypermutation with signs of antigen selection.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox